Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Dr. Reddy's Laboratories Ltd.
Change Company   
BSE Code 500124
ISIN Demat INE089A01031
Book Value 375.79
NSE Code DRREDDY
Dividend Yield % 0.63
Market Cap 1055924.53
P/E 32.80
EPS 38.58
Face Value 1  
13-May-2026 Dr. Reddy's Laboratories reports 86% plunge in Q4...
29-Apr-2026 Dr. Reddy's Lab gets Health Canada’s nod for Gene...
29-Apr-2026 Dr. Reddy’s Laboratories informs about updates
24-Apr-2026 Clarification sought from Dr Reddys Laboratories...
24-Apr-2026 Dr. Reddy’s Laboratories informs about clarificat...
23-Apr-2026 Clarification sought from Dr Reddys Laboratories...
09-Apr-2026 Dr. Reddy’s Laboratories informs about compliance...
08-Apr-2026 Dr. Reddy's Laboratories to sell entire sharehold...
21-Mar-2026 Dr. Reddy’s Laboratories launches Semaglutide inj...
21-Mar-2026 Dr. Reddy’s Laboratories informs about media rel...
21-Mar-2026 Dr Reddys Laboratories informs about press release
06-Mar-2026 Dr. Reddy's Laboratories gets EIR for Andhra Prad...
05-Mar-2026 Dr. Reddy’s Laboratories informs about updates
19-Feb-2026 Dr. Reddy's acquires specialty brands Progynova, ...
19-Feb-2026 Dr. Reddy's rises on acquiring specialty brands P...
Page 1 of 3
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.